Home > Healthcare > Pharmaceuticals > Finished Drug Form > Paracetamol IV Market

Paracetamol IV Market Share

Report ID: GMI12321
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Paracetamol IV Market Share

The competitive landscape in the market is characterized by a mix of global pharmaceutical companies and regional players. Established pharmaceutical giants offer well-known IV formulations of paracetamol under various brand names. Additionally, several generic drug manufacturers contribute to market competition by offering cost-effective alternatives. Companies are focusing on product differentiation, regulatory approvals, and strategic partnerships to strengthen their position in this competitive market.

Paracetamol IV Market Companies

Few of the prominent players operating in the paracetamol IV industry include:

AdvaCare Pharma
Altan Pharma
B. Braun SE
Cipla Inc.
Criticine Care
Fresenius Kabi
GNova Biotech
Lupin
Mallinckrodt Pharmaceuticals
Pfizer
Solitaire Pharmacia
Unital Pharmaceuticals

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global paracetamol IV industry was valued at USD 860.7 million in 2024 and is estimated to grow at a 4.2% CAGR from 2025 to 2034, driven by its effective analgesic and antipyretic properties.

The surgical segment was valued at USD 642.3 million in 2024, primarily due to its widespread use in postoperative pain management and fever reduction, reducing the need for opioid analgesics.

The U.S. paracetamol IV market was valued at USD 340.4 million in 2024, driven by the rising demand for effective pain management solutions and strong regulatory support.

Key players in the industry include AdvaCare Pharma, Altan Pharma, B. Braun SE, Cipla Inc., Criticine Care, Fresenius Kabi, GNova Biotech, Lupin, Mallinckrodt Pharmaceuticals, and Pfizer.